The patents, already approved in the U.S., were recently accepted in Europe and Canada.
Stratum Nutrition (Carthage, MO), a business of ESM Technologies LLC, says that a patent for its eggshell membrane ingredient, plus a patent for a clinical trial model for joint health, have been accepted in Europe and Canada, respectively.
The first patent was issued in the U.S. in 2019 (US 10,328,104) and applies to the use of eggshell membrane ingredient in relation to conditions and disease involving NF-kB dysregulation, including in the pulmonary, gastrointestinal, cardiovascular, and nervous systems. This patent, titled “Methods for Treating NF-kB Dysregulation in a Host in Need Thereof Using Eggshell Membrane Compositions,” has now been accepted by the European Patent Office.
The second patent is for a clinical trial model that uses the cartilage degradation biomarker CTX-II to “evaluate articular joint therapeutics for chondroprotective efficacy.” This patent, first issued in the U.S. in 2018 (US 9,983,214), has now been accepted by the Canadian Intellectual Property Office.
“We are excited to extend our patent protection to additional geographies,” said Kevin Ruff, Stratum’s senior director of scientific and regulatory affairs, in a press release. “This is particularly true for our CTX-II clinical model patent, which has now been allowed in the U.S., Europe, Canada, Japan, and several other countries. We have used this patented model in multiple clinical trials to demonstrate that our flagship ingredient, NEM brand eggshell membrane, helps to protect cartilage in exercising individuals.”